In the first decade of this millennium, convincing data showing that screening for and treatment of gestational diabetes mellitus improve both maternal and fetal outcomes1,2 ended debates within the obstetrical community about the usefulness of screening for gestational diabetes. Essentially all U.S. professional societies now recommend universal biochemical screening with an oral glucose-tolerance test (OGTT) at 24 to 28 weeks’ gestation.3 Accordingly, current research aims to improve the benefits of screening for gestational diabetes and to minimize potential harms. Although some sources have recommended glucose-tolerance testing in early pregnancy for women at high risk for diabetes,4 a recent randomized trial . . .
Funding and Disclosures
Print Subscriber? Activate your online access.